News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lycera Announces Key Appointments to Board of Directors


2/15/2012 7:26:02 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that Steven Gillis, Ph.D., managing director of ARCH Venture Partners, has been appointed chairman of the board of directors, replacing Jeffrey Leiden, M.D., Ph.D., of Clarus Ventures, who has stepped down from the board. The company also announced that Michael Steinmetz, Ph.D., managing director of Clarus Ventures, has joined the board of directors.

Read at BioSpace.com


comments powered by Disqus
Lycera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES